Intravenous leiomyomatosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 22: Line 22:


==Differentiating Intravenous Leiomyomatosis from other Diseases==
==Differentiating Intravenous Leiomyomatosis from other Diseases==
*When the IVC is involved the differential diagnosis should include renal malignancies and primary leiomyoma or sarcoma, as well as thrombosis of the IVC.  
*When the IVC is involved the differential diagnosis should include renal malignancies and primary leiomyoma or sarcoma, as well as thrombosis of the intravenous cathetor.  
*IVLM should be considered in young women with cardiac symptoms who have a right atrial mass as well as a pelvic mass or who have previously undergone hysterectomy for leiomyoma uterus with intravenous involvement.
*Intravenous leiomyomatosis should be considered in young women with cardiac symptoms who have a right atrial mass as well as a pelvic mass or who have previously undergone hysterectomy for leiomyoma uterus with intravenous involvement.


==Complications==
==Complications==

Revision as of 19:53, 14 April 2016

WikiDoc Resources for Intravenous leiomyomatosis

Articles

Most recent articles on Intravenous leiomyomatosis

Most cited articles on Intravenous leiomyomatosis

Review articles on Intravenous leiomyomatosis

Articles on Intravenous leiomyomatosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Intravenous leiomyomatosis

Images of Intravenous leiomyomatosis

Photos of Intravenous leiomyomatosis

Podcasts & MP3s on Intravenous leiomyomatosis

Videos on Intravenous leiomyomatosis

Evidence Based Medicine

Cochrane Collaboration on Intravenous leiomyomatosis

Bandolier on Intravenous leiomyomatosis

TRIP on Intravenous leiomyomatosis

Clinical Trials

Ongoing Trials on Intravenous leiomyomatosis at Clinical Trials.gov

Trial results on Intravenous leiomyomatosis

Clinical Trials on Intravenous leiomyomatosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Intravenous leiomyomatosis

NICE Guidance on Intravenous leiomyomatosis

NHS PRODIGY Guidance

FDA on Intravenous leiomyomatosis

CDC on Intravenous leiomyomatosis

Books

Books on Intravenous leiomyomatosis

News

Intravenous leiomyomatosis in the news

Be alerted to news on Intravenous leiomyomatosis

News trends on Intravenous leiomyomatosis

Commentary

Blogs on Intravenous leiomyomatosis

Definitions

Definitions of Intravenous leiomyomatosis

Patient Resources / Community

Patient resources on Intravenous leiomyomatosis

Discussion groups on Intravenous leiomyomatosis

Patient Handouts on Intravenous leiomyomatosis

Directions to Hospitals Treating Intravenous leiomyomatosis

Risk calculators and risk factors for Intravenous leiomyomatosis

Healthcare Provider Resources

Symptoms of Intravenous leiomyomatosis

Causes & Risk Factors for Intravenous leiomyomatosis

Diagnostic studies for Intravenous leiomyomatosis

Treatment of Intravenous leiomyomatosis

Continuing Medical Education (CME)

CME Programs on Intravenous leiomyomatosis

International

Intravenous leiomyomatosis en Espanol

Intravenous leiomyomatosis en Francais

Business

Intravenous leiomyomatosis in the Marketplace

Patents on Intravenous leiomyomatosis

Experimental / Informatics

List of terms related to Intravenous leiomyomatosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Synonyms and keywords: Nesidioblastoma

Overview

  • Intravenous leiomyomatosis (IVLM) is characterized by the extension into venous channels of histologically benign smooth muscle tumor arising from either the wall of a vessel or from a uterine leiomyoma.
  • Fewer than 100 cases have been reported in all, and only 14 cases involved intracardiac extension from the IVC.
  • In one reported case, this slowly growing invasive neoplasm extended not only into the heart but into both pulmonary arteries as well. [1]

Pathophysiology

  • The etiology of IVLM is unclear. All described patients are female, and most are white, premenopausal, and parous.
  • The median age is 45 years, with patients ranging from 26 to 70 years old.
  • The patients may be asymptomatic or have symptoms of uterine leiomyomas.
  • Patients with obstruction of the right atrium may present with syncopal episodes, dyspnea on exertion, shortness of breath, etc.
  • The tumor is slow growing, and the prognosis is favorable.

Differentiating Intravenous Leiomyomatosis from other Diseases

  • When the IVC is involved the differential diagnosis should include renal malignancies and primary leiomyoma or sarcoma, as well as thrombosis of the intravenous cathetor.
  • Intravenous leiomyomatosis should be considered in young women with cardiac symptoms who have a right atrial mass as well as a pelvic mass or who have previously undergone hysterectomy for leiomyoma uterus with intravenous involvement.

Complications

  • Although embolization of the tumor represents a theoretical risk, this has not been reported.
  • The tumor can recur, and repeat operation may be necessary.
  • Most reported deaths involved extension of the tumor into the heart, with death due to mechanical obstruction rather than the neoplastic process per se
  • Intravenous leiomyomatosis should not be confused with benign metastasizing leiomyoma, in which a benign uterine leiomyoma is associated with a benign smooth muscle tumor located in the parenchyma of a distant organ, such as lung.
  • Intravenous leiomyomatosis is confined to vessels, whereas benign metastasizing leiomyoma shows no relation to vascular channels.

Images

Example #1

Patient presented with S.O.B. one year after hysterectomy for a leiomyomatous uterus (Images shown below are courtesy of RadsWiki and copylefted}




Related Chapters

References

  1. DJ Kaszar-Seibert, GP Gauvin, PA Rogoff, FJ Vittimberga, S Margolis, AD Hilgenberg, DK Saal, and GO Goldsmith. Intracardiac extension of intravenous leiomyomatosis. Radiology 1988 168: 409-410.


Template:WikiDoc Sources